Novartis launches study using smartphone app on MS

Novartis, producers of innovative healthcare solutions, has announced the launch of its elevateMS study. The study aims to utilize a mobile application for people with multiple sclerosis (MS) to collect sensor-based data to improve research.

The study incorporates a mobile app that allows participants to complete questionnaires, capture passive and active movement data, and complete functional tasks. Data are stored on the app where participants are able to view changes over time and inform researchers about living with MS.

"As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe," said Stanley Cohan, MD, PhD, medical director of Providence Multiple Sclerosis Center in Portland, Oregon. "With the elevateMS app, study participants can frequently document their symptoms in a personal health story. In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.